Articles

A new facility near Frankfurt, Germany expands Avantor's geographic reach and supports the growing demand for scientific research and clinical trial sample storage.

Avantor Opens Biorepository Facility in Germany 

The new super plant, being built in Incheon, South Korea, will have a total biopharmaceutical manufacturing capacity of 256,000 L.

Samsung Biologics Begins Construction on Fourth Biopharma Manufacturing Plant 

The companies have formed a long-term manufacturing agreement to accelerate the global supply for Lilly’s COVID-19 antibody therapeutics.

Samsung Biologics and Lilly Partner to Accelerate Delivery of COVID-19 Antibody Therapeutics

The agreement follows a recent announcement that Sartorius plans to invest $100 million in Songdo, South Korea’s bio cluster.

Samsung Biologics Signs MOU with Sartorius to Enhance Supply Chain for Biomedicines

The agreement will allow Roche to use CEVEC’s proprietary ELEVECTA technology, which is designed to enable fully scalable, high-performance AAV vector production in suspension bioprocesses.

Roche in Agreement to Use CEVEC’s ELEVECTA Technology for AAV Manufacture

The partners have established PathoQuest, Inc., a US subsidiary, and will construct an NGS-based testing lab at Charles River’s Wayne, PA, site. 

Charles River and PathoQuest Establish US Subsidiary for NGS-based Testing Lab 

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

The Trump administration unveiled a new drug price control policy, drawing opposition from pharma manufacturers and pharmacy benefit managers.

Trump’s Revenge on Pharma

When administered together in clinical trials, casirivimab and imdevimab were shown to lessen COVID-19 hospitalization or emergency room visits in patients at high risk for disease progression within 28 days after treatment when compared to placebo. 

FDA Issues EUA for COVID-19 Monoclonal Antibody Treatment

An independent data safety monitoring board found that clinical trial data demonstrated that the vaccine candidate met its primary endpoint and demonstrated protection from COVID-19.

AstraZenca Vaccine Candidate ‘Highly-Effective’ in Preventing COVID-19

Following an EUA application from Pfizer and NioNTech, FDA outlines the process for committee and agency review. 

News